Objective: To examine the influence of the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism on longitudinal cognitive trajectories in a large, cognitively healthy cohort enriched for Alzheimer disease (AD) risk and to understand whether b-amyloid (Ab) burden plays a moderating role in this relationship.
Preclinical Alzheimer disease (AD) is thought to be a critical period for intervention therapies that could potentially delay or prevent AD onset. 1 Considerable focus has been placed on genetic and environmental risk factors that may play a role in progression to AD and are possibly targetable for intervention, including APOE e4, 2,3 physical activity, 4, 5 and cognitive reserve. 6, 7 Increasing evidence suggests that brain-derived neurotrophic factor (BDNF) may be a genetic risk factor for AD. BDNF is a neurotrophin known to play roles in synaptic plasticity, neurogenesis, neuronal survival, and cognitive health. [8] [9] [10] Additional research suggests that BDNF may moderate b-amyloid (Ab) accumulation, a hallmark feature of AD, 1 by reducing Ab-mediated cell death, 11 decreasing Ab formation, 12 and repairing Ab-induced damage.
A polymorphism within the BDNF gene (rs6265) causes a valine (Val) to methionine (Met) substitution at codon 66 (Val66Met). Carriage of 1 or 2 Met alleles is associated with lower BDNF production, 14 decreased hippocampal volume, 15 and cognitive decline. [16] [17] [18] [19] However, null 20, 21 and opposite findings 22, 23 have been documented, making the relationship between BDNF and cognition in aging populations unclear.
Our primary objective was to investigate whether BDNF is associated with longitudinal cognitive trajectories within a large cohort of middle-aged, cognitively healthy individuals enriched for AD risk, a target population for interventional therapies. Our secondary objective was to determine whether Ab burden moderates the aforementioned relationship. We hypothesized that BDNF Met carriers would exhibit comparatively steeper cognitive decline in all cognitive domains and that Ab burden would exacerbate this cognitive vulnerability.
METHODS Standard protocol approvals, registrations, and patient consents. The University of Wisconsin
Institutional Review Board approved all study procedures, and all participants provided signed informed consent before participation.
Participants. Study participants were enrolled in the Wisconsin
Registry for Alzheimer's Prevention (WRAP), a longitudinal study of persons 40 to 65 years of age and cognitively healthy at study entry. Details about WRAP have been previously described. 24 For this study, 1,410 participants were selected on the basis of available BDNF and APOE data. One hundred five were subsequently excluded because of self-reported neurologic diagnosis (multiple sclerosis, Parkinson disease, etc). To preclude the influence of sibling clusters, only the first enrolled sibling from a family was included, excluding 277 individuals. Five participants were excluded because of missing covariate data. Thus, 1,023 individuals were included in the study. This sample is enriched for AD risk, with 64.2% of participants having at least one parent with AD as defined by National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association research criteria and 38.0% being APOE e4 positive. Table 1 gives participant characteristics.
DNA collection, genotyping, and quality assurance. DNA was extracted from whole-blood samples with the PUREGENE DNA Isolation Kit (Gentra Systems, Inc, Minneapolis, MN). DNA concentrations were quantified with ultraviolet spectrophotometry (DU 530 Spectrophotometer; Beckman Coulter, Fullerton, CA). Single nucleotide polymorphisms (SNPs) for BDNF (rs6265) and APOE (rs429358, rs7412) were genotyped by LGC Genomics (Beverly, MA) using competitive allelespecific PCR-based KASP genotyping assays. For quality assurance, duplicate quality control samples from 102 individuals were placed randomly throughout each of the 96-well plates. Further quality assurance was conducted with PLINK version 1.07. 25 BDNF and APOE SNPs did not deviate from Hardy-Weinberg equilibrium with the use of a Bonferroni-adjusted global significance level of p 5 0.05, with accordant allele call rates $95%.
Cognitive evaluation. The WRAP neuropsychological test battery 24 comprises measures that assess multiple cognitive domains. Prior factor analyses of these measures indicated they map onto 6 cognitive factors; details of this method have been previously described. 26 Four of these factor scores were included in the present study because of their representation of cognitive abilities implicated in AD. 27 These factors and their constituent tests are as follows: immediate memory-Rey Auditory Verbal Learning Test (RAVLT) Learning Trials 1 and 2; verbal learning and memory-RAVLT Learning Trials 3 through 5 and Delayed Recall; working memory-Digit Span and Letter-Number Sequencing subtests from the Wechsler Adult Intelligence Scale, third edition; and speed and flexibility-Stroop ColorWord Test Interference Trial and Trail-Making Tests A and B. Participants undergo cognitive evaluation at each study visit, with up to 5 visits completed and a maximum of 13.12 years of followup at the time of these analyses (table 1).
C-Pittsburgh compound B-PET neuroimaging protocol.
A subset of participants (n 5 140) underwent 3-dimensional 11 C-Pittsburgh compound B (PiB)-PET scanning on a Siemens EXACT HR1 scanner (Siemens AG, Erlangen, Germany) through participation in a WRAP-affiliated study. Detailed methods of the acquisition and postprocessing of PiB-PET data have been described previously. 4 Briefly, imaging entailed a 70-minute dynamic scan on bolus injection and a 6-minute transmission scan. Image postprocessing used an in-house automated pipeline. 28 We created distribution volume ratio (DVR) maps of 11 C-PiB binding using the time-activity curve in the gray matter of the cerebellum as a reference region. 29 Then, using an anatomic atlas, 30 we extracted quantitative DVR data from 8 bilateral regions of interest sensitive to Ab accumulation, including the precuneus, posterior cingulate, orbitofrontal cortex, anterior cingulate, angular gyrus, supramarginal gyrus, middle temporal gyrus, and superior temporal gyrus. DVR data from these regions of interest were combined to form a continuous, composite measure of Ab accumulation. 31 The mean time interval between PiB-PET scan and baseline WRAP visit was 6.08 6 1.68 years (table 1) .
Statistical analyses. We used linear mixed models to investigate differences in the 4 cognitive trajectories as a function of BDNF Val66Met polymorphism. Models were fit by use of the maximum likelihood estimation and were constructed in the following progressive steps (assuming normality in the random effects): random intercept only, random intercept and random slope (for time, measured in years since baseline visit) without correlation between the 2 (i.e., variance components covariance matrix), and random intercept and slope with correlation between the 2 (i. e., unstructured covariance matrix). The last was selected for all subsequent analyses on the basis of superior model fit (Akaike information criterion). After the covariance structure was decided, we then added fixed-effects covariates, which were determined a priori from known associations with cognition or AD. They included age at baseline visit, sex, years of education, APOE e4 status (0 5 no e4 allele, 1 5 1 or 2 e4 alleles), parental family history of AD (0 5 negative parental history, 1 5 positive parental history), time, and BDNF (0 5 Val/Val homozygotes, 1 5 Met carriers; table 1). Our term of interest was BDNF 3 time because it would indicate whether rates of decline in cognition 32 In addition, raw data visualization of each primary analysis confirmed that linearity was a reasonable representation of the data (figure e-1 at Neurology.org).
Given a significant BDNF 3 time term, follow-up analyses were conducted to elucidate which cognitive tests contributing to the factor scores drove the observed associations. We fitted the same mixed-effects models as above, except outcomes were the individual cognitive test scores rather than factor scores. Our term of interest remained the BDNF 3 time interaction.
In addition, we performed secondary mixed-effects models to determine whether Ab burden, as indexed by the continuous composite PiB-PET measure, modified any BDNF 3 time effect observed in our primary analyses. For this purpose, we incorporated terms for Ab, BDNF 3 Ab, Ab 3 time, and Ab 3 BDNF 3 time into our original models, with Ab 3 BDNF 3 time being the term of interest. All follow-up analyses to our primary analyses were not corrected for multiple comparisons because of their exploratory nature. Unless specified above, SPSS default mixedmodel specifications were used for all analyses. Details on mixedmodeling procedures and assumptions are described elsewhere. 33 Only findings with values of p # 0.05 (2-tailed) were considered significant. Analyses were conducted with IBM SPSS, version 21.0.
RESULTS Background characteristics. Participant background characteristics are described in table 1. The mean 6 SD age at baseline was 54.94 6 6.41 years; women made up 69.7% of the sample. The group was highly educated (mean 6 SD education 16.36 6 2.82 years) and primarily white (88.7%, self-reported). In our sample, BDNF Met carriers encompassed 32.3% of the sample, which is lower than the reported white population frequency of 37.0% (http://www.alzgene.org). In a comparison of BDNF Val/Val homozygotes and BDNF Met carriers, there were no differences in demographic characteristics except for race/ethnicity (p , 0.001). There were no differences in demographic characteristics in the subset of 140 individuals with PiB-PET data. (table 1) , we repeated the analyses while additionally including race/ethnicity as a covariate. Results were substantively unchanged.
Follow-up analyses were conducted to determine which cognitive tests in verbal learning and memory and speed and flexibility drove the associations noted above. For verbal learning and memory, both measures, RAVLT Learning Trials 3 through 5 and Delayed Recall, showed associations wherein BDNF Met carriers declined more steeply over time compared with BDNF Val/Val homozygotes (p 5 0.005 and 0.007, respectively; table 2). For speed and flexibility, none of the 3 constituent tests showed associations with BDNF.
Influence of Ab and BDNF on cognitive trajectories.
Given the BDNF 3 time interactions observed in verbal learning and memory and speed and flexibility in our primary analyses, we performed secondary analyses investigating whether the relationships observed were modified by Ab burden. Results showed that there was an Ab Of note, refitting our original BDNF 3 time analyses within this PiB subsample did not yield In addition, we examined whether APOE e4 status moderated the relationship between BDNF and cognitive trajectories in verbal learning and memory and speed and flexibility. The findings were nonsignificant (p 5 0.359 and 0.686, respectively). DISCUSSION This study found that the BDNF Val66Met polymorphism is associated with cognitive decline in a large cohort of individuals with increased risk for AD. Specifically, compared with Val/Val homozygotes, Met carriers exhibited steeper decline in the cognitive domains of verbal learning and memory and speed and flexibility. In addition, we showed that Ab accumulation adversely moderated the relationship between BDNF and verbal learning and memory such that Met carriers with greater Ab burden had steeper memory decline compared to those with lesser Ab burden. This is one of few longitudinal studies to report the association between the BDNF Val66Met polymorphism and cognitive decline over time. Our study also expands on previous findings regarding the moderating relationship between Ab accumulation and Met carriership on cognitive decline. 16 Our research was conducted in a cognitively healthy cohort with risk factors for AD, highlighting the potential for early detection of cognitive decline and subsequent implementation of interventional therapies 36 during this preclinical AD phase. Our study adds longitudinal evidence to a growing body of literature on the relationship between the BDNF Val66Met polymorphism and cognitive health. Initial cross-sectional studies on this polymorphism found that in younger adults, Met carriership was associated with worse episodic memory as measured by the Wechsler Memory Scale and an fMRI declarative memory paradigm. 14, 19 More recently, a study in an aging population 18 (mean age 56 years) demonstrated cross-sectionally that Met carriers performed worse in both item memory and prospective memory with advancing age compared with Val/Val homozygotes. Item memory was assessed with the California Verbal Learning Test, 18 a psychometric measure similar to the RAVLT, which comprises our verbal learning and memory measure. Another crosssectional study 17 showed that in addition to memory, processing speed was reduced in Met carriers compared to Val/Val homozygotes (mean age 63 years). Our study adds evidence to these findings by demonstrating that in a longitudinal cohort at risk for AD, Met carriership was associated with steeper decline in the domains of verbal learning and memory and speed and flexibility over an average time period of 7 years. However, other work examining the relationship between the BDNF Val66Met polymorphism and cognitive health has failed to find a relationship or has even observed findings that are opposite to the aforementioned. In one study, Val/Val genotype occurred with higher frequency in those with AD compared to healthy controls 22 ; another study showed lower scores on the Frontal Assessment Battery in Val/Val homozygote patients with mild AD. 23 These discrepancies could possibly be explained by genetic differences between samples (i.e., lack of Hardy-Weinberg equilibrium), differences in disease stage at the time of analysis (probable AD vs preclinical AD), or cross-sectional design. In fact, in the present study, Met carriers performed better at baseline in the domains of verbal learning and memory (p 5 0.013) and speed and flexibility (p 5 0.002) (table 2) yet declined more steeply over time, emphasizing the importance of longitudinal design in studies of BDNF and cognition.
Other studies have failed to find a relationship between the Val66Met polymorphism and cognitive outcomes or AD incidence. 15, 20, 21 However, in one of these studies, the authors reported relationships between greater BDNF expression in the dorsolateral prefrontal cortex and slower cognitive decline. 21 Another group did not find associations with the polymorphism but noted that greater serum BDNF levels resulted in reduced dementia and AD incidence. 20 Finally, a third report did not find associations with the Val66Met polymorphism but did with other BDNF SNPs, specifically rs1157659, rs11030094, and rs11030108. 15 These discrepancies underscore the need for further understanding of the intricacies in the relationship between BDNF polymorphisms, BDNF expression, and cognitive function.
We found that greater Ab accumulation, as measured by PiB load in 8 bilateral regions of interest, moderated the relationship between BDNF and verbal learning and memory such that in Met carriers, those with greater Ab accumulation had steeper cognitive decline. This finding aligns with a similar report 16 that found that in cognitively healthy older adults (mean age 71 years), Met carriers with high levels of Ab exhibited steeper cognitive decline in episodic memory, executive function, and language over 36 months. The same group also observed that among persons with amnestic mild cognitive impairment, Met carriers with high levels of Ab had worse episodic memory. 37 Other groups have noted similar moderating effects of Ab and BDNF on cognition in older adults. 38 This interaction between Ab and the BDNF Val66Met polymorphism adds further support for the potential role the BDNF protein has in moderating Ab production, thus protecting cognitive function. Animal studies have indicated that BDNF regulates sorting protein-related receptor with A-type repeats, a known modulator of Ab precursor protein trafficking and processing, via extracellular signalregulated protein kinase stimulation, suggesting that BDNF could deter amyloid production. 12 Other studies have found that BDNF delivery rescues memory impairment in mice injected with Ab 1-42 , 39 prevents neuronal loss, 11 and rescues cells from degeneration due to Ab toxicity. 13 It is critical for future studies to further investigate the role that the BDNF gene and BDNF protein may have in Ab accumulation because it could be a potential target for intervention against Ab toxicity.
A major strength of this study is its scale. With 1,023 individuals and up to 13 years of follow-up, it is the one of the largest studies investigating the BDNF Val66Met polymorphism. In addition, conducting the study within the WRAP cohort provides further evidence that subtle cognitive changes can be detected early in the AD cascade, and intervention during this time period could be critical for delaying or preventing onset of AD. However, this study is not without limitations. Our sample consists of predominantly highly educated, white individuals, reducing the generalizability of our results. Generalizability might also be reduced by the discord between Met carriers in our sample and the white population frequency. Furthermore, the sample size of individuals with PiB-PET data was limited. In addition, we were able to conduct analyses using only one BDNF polymorphism, and no serum BDNF data were available for this research. Ongoing work in our group will further examine the interplay between BDNF polymorphisms, systemic and central BDNF levels, and neuroimaging and cognitive outcomes. We find this research to be of particular importance, especially given the body of research suggesting that BDNF levels can be increased with physical activity 5 and other modifiable lifestyle factors. 40 This study provides evidence that the BDNF Val66Met polymorphism is associated with cognitive decline in a large sample of individuals at risk for AD and that Ab plays a moderating role in this relationship. Our findings suggest that Met carriership could accelerate cognitive decline throughout the preclinical phase of AD, emphasizing the importance of investigating BDNF as a potential target for novel AD therapeutics in the future. 36 
